Evaluating outcomes of endoscopic treatment for gastrointestinal lesions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the clinical outcomes for patients undergoing endoscopic resection of suspected premalignant and malignant gastrointestinal lesions at Interventional Endoscopy Services. The primary focus is on achieving curative endoscopic resection, while secondary outcomes include the techniques used for resection, rates of en bloc resection, and the incidence of adverse events such as infection, bleeding, perforation, and mortality, along with one-year survival rates. The study will gather data from patients referred for this specific treatment to evaluate effectiveness and safety.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients age \>18 years that have been referred for endoscopic treatment of GI lesions.

Exclusion Criteria:

* Patients for whom endoscopic treatment was not performed.

Where it's running

• Interventional Endoscopy Services
  San Francisco, California, United States Recruiting

Study contacts

• Principal investigator: Kenneth F Binmoeller, M.D. — California Pacific Medical Center
• Study coordinator: Jona C Bernabe
• Email: jona.bernabe@sutterhealth.org
• Phone: 415-600-1151

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Preoperative Muscle Health and Postoperative Outcomes in Older Adults with GI Cancer

  This study looks at whether having sarcopenia before surgery affects recovery and complications after GI cancer surgery in people 60 and older.

  Recruiting Van Training and Research Hospital · Van, Van · NCT07817758

• Velzatinib for advanced GIST after multiple prior TKIs

  This study tests velzatinib to see if it can shrink or slow tumors in people with metastatic or unresectable GIST who have progressed on or could not tolerate standard therapies.

  Recruiting at 3 sites Phase 2 GlaxoSmithKline · Fukuoka and 2 other locations · NCT07689201

• Romiplostim N01 plus ATRA for persistent low platelets after cancer remission

  This study tests whether adding all-trans retinoic acid to Romiplostim N01 helps people who still have low platelets after GI/digestive system cancer remission reach safer platelet levels.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07586813

• Fecal transplant for chemotherapy and targeted-therapy gut side effects in advanced gastrointestinal cancer

  This trial will try oral fecal microbiota transplants (FMT) to see if they reduce chemotherapy or targeted-therapy–related gut symptoms in adults with advanced gastrointestinal cancers.

  Recruiting Phase 1 Second Affiliated Hospital, Zhejiang University, School of Medicine · Zhejiang, Hangzhou · NCT07319364

• PF-08634404 plus chemotherapy for adults with metastatic colorectal cancer

  This trial will test whether adding a new drug called PF-08634404 to standard chemotherapy helps adults whose colorectal cancer has spread.

  Recruiting at 343 sites Phase 3 Pfizer · Chandler, Arizona and 371 other locations · NCT07222800

• IDRX-42 versus sunitinib for adults with advanced gastrointestinal stromal tumors after imatinib

  This test compares IDRX-42 (GSK6042981) with sunitinib in adults with advanced or unresectable GIST who have already been treated with imatinib to see which controls the cancer better and is safer.

  Recruiting at 156 sites Phase 3 GlaxoSmithKline · Phoenix, Arizona and 155 other locations · NCT07218926

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.